Bernstein sees TI’s likely price hike benefiting Infineon, Renesas stock
Akero Therapeutics, Inc. (NASDAQ:AKRO), a $4.32 billion market cap biotech company, saw Senior Vice President, Commercial Strategy, Patrick Lamy, sell 2,000 shares of common stock on June 16, 2025, for approximately $108,271. The shares were sold in two transactions with prices ranging from $53.817 to $55.092, near the stock’s 52-week high of $58.40. According to InvestingPro analysis, the stock is currently fairly valued.
On the same day, Lamy also exercised options to acquire 2,000 shares of Akero Therapeutics common stock at a price of $19.87, for a total value of $39,740.
Following these transactions, Lamy directly owns 32,573 shares of Akero Therapeutics.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on January 6, 2025.
In other recent news, Akero Therapeutics has reported promising results from its Phase 2b SYMMETRY trial, published in the New England Journal of Medicine, showcasing the potential of its drug efruxifermin (EFX) in improving liver fibrosis for patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). The trial results indicated significant improvements in fibrosis without worsening MASH, with 29% of the EFX 50mg group showing improvement at week 96 compared to 11% in the placebo group. Akero’s financial position remains robust, with $1.1 billion in cash reserves, expected to support operations into 2028. Analysts from Jefferies maintain a Buy rating with a $75 target, highlighting the strong data from Akero’s FGF21 therapy and its potential market opportunity. Citi also maintains a Buy rating while slightly lowering its price target to $78, reflecting Akero’s recent earnings and clinical data releases. Meanwhile, Morgan Stanley (NYSE:MS) adjusted its price target to $84, maintaining an Overweight rating, citing a more cautious timeline for the U.S. launch of EFX treatments. Clear Street initiated coverage with a Buy rating and a $49 target, emphasizing EFX’s strong efficacy in treating NASH and its potential to become a leading treatment option. Akero continues to advance its clinical programs, including the Phase 3 SYNCHRONY program, with results anticipated in 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.